Background: Chronic hepatitis C virus (HCV) is a worldwide health problem
that can lead to liver cirrhosis, liver cell failure and numerous subsequent complications
such as hepatocellular carcinoma. Till the near past, pegylated interferon was the standard
of care therapy. However, it was associated with suboptimal success rates and many side
effects. Thereafter, direct antiviral agents (DAA) appeared and played the key role in
management of HCV. One of those recent DAAs is ravidasvir.
Summary: It is a potent NS5A inhibitor that was formerly known as PPI-668. It is produced
by the cooperation of Presidio pharmaceuticals and Pharco International pharmaceutical
company. Since its first production, it has been enrolled in different successive
clinical trials. Phase 1 and 2 trials confirmed its safety and tolerability and its great efficacy
in suppressing viral loads in short periods. It has a pangenotypic activity with favorable
pharmacokinetic properties. Ravidasvir inhibits the replication of HCV variants that develop
resistance mutations for different DAA classes. Even more, HCV variants that had
reduced susceptibility to ravidasvir are completely susceptible to other DAA. Finally, a
large multicenteric registrational phase 3 clinical trial that included large percentages of
difficult to treat patients (such as cirrhotic and interferon experienced patients) has been
fully accomplished and proved great SVR12 rates.
Conclusion: Ravidasvir is a potent new NS5A inhibitor with excellent safety and tolerability
in management of genotype 4 HCV patients.